Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.

The pharmacogenomics journal - 1 Oct 2009

Caronia D, Patiño-García A, Milne R L, Zalacain-Díez M, Pita G, Alonso M R, Moreno L T, Sierrasesumaga-Ariznabarreta L, Benítez J, González-Neira A

Abstract excerpt

Platinum agents cause DNA cross-linking. Nucleotide excision repair genes play a key role in DNA damage repair. This study aims to investigate whether polymorphisms in these genes are associated with tumor response and survival in cisplatin-treated osteosarcoma patients. Eight single nucleotide polymorphisms in ERCC2, XPC, XPA, ERCC1, ERCC4 and ERCC5 genes were analyzed in 91 patients diagnosed with osteosarcoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Neoplasms
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Hearing Loss

Share to Osteosarcoma

Share to Patient Selection

Share to Proportional Hazards Models

Share to Xeroderma Pigmentosum Group D Protein

Source

Identifiers

PMID: 19434073
DOI: 10.1038/tpj.2009.19

Genes

ERCC2
XPC
ERCC1
ERCC4
ERCC5
XPA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.PMID 19434073Read ↗

The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.Semantic proximity Read ↗

Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma.Semantic proximity Read ↗

Influence of ERCC2 gene polymorphisms on the treatment outcome of osteosarcoma.Semantic proximity Read ↗

Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy.Semantic proximity Read ↗

Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma.Semantic proximity Read ↗

The association between DNA repair genes polymorphisms and cisplatin-induced ototoxicity in cancer patients: a systematic review.Semantic proximity Read ↗

ERCC polymorphisms and prognosis of patients with osteosarcoma.Semantic proximity Read ↗

Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.Semantic proximity Read ↗

Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.Semantic proximity Read ↗

Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing.Semantic proximity Read ↗

Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients.Semantic proximity Read ↗

Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.